Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?

Genomics - 1 Sept 2022

Saifi Sheeba, Ravi Varsha, Sharma Sparsh, Swaminathan Aparna, Chauhan Nar Singh, Pandey Rajesh

Abstract excerpt

The global COVID-19 pandemic continues due to emerging Severe Acute Respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC). Here, we performed comprehensive analysis of in-house sequenced SARS-CoV-2 genome mutations dynamics in the patients infected with the VOCs - Delta and Omicron, within Recovered and Mortality patients. Statistical analysis highlighted significant mutations - T4685A,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Drug Treatment
Share to Molecular Docking Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pandemics

Share to RNA-Dependent RNA Polymerase

Share to SARS-CoV-2

Share to SARS-CoV-2 and COVID-19 Research

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 36041637
DOI: 10.1016/j.ygeno.2022.110466
PMCID: PMC9419439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 VOCs, Mutational diversity and clinical outcome: Are they modulating drug efficacy by altered binding strength?PMID 36041637Read ↗

A hijack mechanism of Indian SARS-CoV-2 isolates for relapsing contemporary antiviral therapeutics.Semantic proximity Read ↗

Clinical evidence of the effectiveness of remdesivir in COVID-19 during periods dominated by Delta and Omicron SARS-CoV-2 variants.Semantic proximity Read ↗

Genomic diversity and molecular dynamics interaction on mutational variances among RB domains of SARS-CoV-2 interplay drug inactivation.Semantic proximity Read ↗

Genomic and proteomic mutation landscapes of SARS-CoV-2.Semantic proximity Read ↗

Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine EffectivenessSemantic proximity Read ↗

Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression.Semantic proximity Read ↗

Emerging SARS-CoV-2 mutation hotspots associated with clinical outcomesSemantic proximity Read ↗

Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity.Semantic proximity Read ↗

SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study).Semantic proximity Read ↗

Impact of clade specific mutations on structural fidelity of SARS-CoV-2 proteinsSemantic proximity Read ↗

Accurate predictions of SARS-CoV-2 infectivity from comprehensive analysis.Semantic proximity Read ↗

Novel Antiviral Therapeutic Against SARS-CoV-2 and its Variants: Recent Developments and Future PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.